You are viewing the site in preview mode

Skip to main content


Table 1 End-points of randomized trials

From: Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review

Trial Patients Study design Primary end-point Secondary end-point
ACT I [2] 560 CRT vs RT LC; RFS; CFS; OS -
Intergroup [3] 310 CRT vs RT LC; CFS; OS; DFS -
EORTC [4] 110 CRT vs RT LC OS; CFS
UKCCCR [18] 856 CRT vs RT LC OS; morbidity
  1. LC local control; RFS: relapse free survival, CFS colostomy free survival, OS overall survival, DFS disease free survival.